Pfizer in $5 billion accelerated buyback deal with Goldman, Sachs & Co
(Reuters) – Drugmaker Pfizer Inc said it entered into an agreement with Goldman, Sachs & Co to buy back $5 billion of its stock. Pfizer said the accelerated share repurchase was assumed in the forecast for the full year it provided last month. Under the agreement, which forms a part of Pfizer's existing buyback authorization, about 150 million shares will be bought. The settlement is expected during or prior to the third quarter. Shares of the New York-based company closed at $33.06 on the New York Stock Exchange on Monday. …